What is SIGA Technologies's market cap?

SIGA Technologies (SIGA) has a market capitalization of $222.3M and trades on NASDAQ.

What is SIGA Technologies's revenue and profitability?

SIGA Technologies generated $93.8M in trailing twelve-month revenue with net income of $25.3M, representing a net margin of 43.2%. Gross margin stands at 65.4%, with free cash flow of $117.8M. These figures are based on the Q1 2026 filing.

Who are SIGA Technologies's competitors?

SIGA Technologies's key competitors include Emergent BioSolutions Inc., Spero Therapeutics, Inc. Common Stock, OSR Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does SIGA Technologies partner with?

SIGA Technologies's notable partners include Meridian Medical Technologies, W.R. Grace and Company, Catalent Pharma Solutions LLC, and others.

Where is SIGA Technologies headquartered?

SIGA Technologies is headquartered in United States of America and employs approximately 45 people. It has been publicly traded since 1997.

SIGA Technologies

SIGA

SIGA Technologies is a commercial-stage pharmaceutical company focused on health security and medical countermeasures for biological threats.

Market cap

$222.34M-53.3%

Revenue$93.8M-22.1%

Net income$25.3M-57.4%

Free cash flow$117.8M+64.8%

EPS (diluted)$0.34-58.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$6.2M EPS-$0.05

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Financials

Q1 2026

Income statement

See full

Revenue$6.2M-11.3%

Gross profit$3.3M-52.0%

Operating income-$5.3M-136%

Net income-$3.5M-746%

EPS (diluted)-$0.05-400%

Balance sheet

See full

Cash & equivalents$145.6M-10.3%

Total debt$601.0K-50.6%

Total equity$151.6M-29.8%

Total assets$219.4M-11.2%

Cash flow

See full

Operating cash flow-$8.7M-223%

CapEx--100%

Free cash flow-$8.7M-223%

Valuation & ratios

Valuation

See full

Market cap$222.34M-53.3%

Enterprise value$77.38M-76.8%

P/E8.8×—

P/S2.4×-0.5×

Profitability

See full

Gross margin65.4%-11.2pp

Returns & leverage

See full

Debt / equity0×0.0×

Current ratio3.2×-5.2×

Segments

By geography

See full

US$6.2M+412%

CA--100%

Competitors

By market cap

Opko Health$936.3M-12.5%

Emergent Biosolutions$378.2M+2.8%

SIGA Technologies$222.3M-56.8%

Arcturus Therapeutics$163.7M-58.0%

Karyopharm Therapeutics$160.7M+326%

Spero Therapeutics, Inc.$68.3M-46.9%

OSR Holdings, Inc.$15.2M-18.6%

60 Degrees Pharmaceuticals$4.2M+1.1%

By revenue growth

Opko Health-11.5%

SIGA Technologies-22.1%

Emergent Biosolutions-29.9%

By net margin

SIGA Technologies43.23%-22.3pp

Emergent Biosolutions9.62%+36.6pp

Opko Health-12.4%+14.3pp

Profile

SIGA Technologies is a commercial-stage pharmaceutical company focused on health security and medical countermeasures for biological threats. The company specializes in the development and commercialization of antiviral solutions for orthopoxviruses, primarily serving as a strategic provider to the U.S. and international governments. Its core value proposition lies in providing essential treatments for high-consequence pathogens like smallpox and other related viral diseases.

Competitive position

SIGA is a leading provider of the only FDA-approved smallpox antiviral, maintaining a significant long-term relationship with the U.S. Strategic National Stockpile.

GeographiesUnited States, European Union, United Kingdom, Canada, Japan

Customer segmentsFederal Governments, Defense Agencies, Public Health Organizations

Business modelGovernment Contracting, B2G (Business-to-Government), Product Manufacturing and Sales, R&D Services

SuppliersContract Manufacturing Organizations (CMOs), Active Pharmaceutical Ingredient (API) suppliers, Specialty chemical providers, Clinical research organizations

CustomersU.S. Strategic National Stockpile, U.S. Department of Defense, International health ministries, Foreign defense departments

CountryUnited States of America

Listed1997

Employees45.0

CEODiem Nguyen

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websitesiga.com

FilingsSEC EDGAR

Ask your AI about SIGA Technologies.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is SIGA Technologies's market cap?: SIGA Technologies (SIGA) has a market capitalization of $222.3M and trades on NASDAQ.
What is SIGA Technologies's revenue and profitability?: SIGA Technologies generated $93.8M in trailing twelve-month revenue with net income of $25.3M, representing a net margin of 43.2%. Gross margin stands at 65.4%, with free cash flow of $117.8M. These figures are based on the Q1 2026 filing.
Who are SIGA Technologies's competitors?: SIGA Technologies's key competitors include Emergent BioSolutions Inc., Spero Therapeutics, Inc. Common Stock, OSR Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does SIGA Technologies partner with?: SIGA Technologies's notable partners include Meridian Medical Technologies, W.R. Grace and Company, Catalent Pharma Solutions LLC, and others.
Where is SIGA Technologies headquartered?: SIGA Technologies is headquartered in United States of America and employs approximately 45 people. It has been publicly traded since 1997.